ABL1 is altered in 0.6% of T-cell and NK-cell neoplasm patients [2].

ABL1 is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

AFF1 is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

BCR is altered in 1.15% of T-cell and NK-cell neoplasm patients [2].

BCR is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BCR status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is altered in 2.39% of T-cell and NK-cell neoplasm patients [2].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

IKZF1 is altered in 1.23% of T-cell and NK-cell neoplasm patients [2].

IKZF1 is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains IKZF1 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is altered in 1.79% of T-cell and NK-cell neoplasm patients [2].

KIT is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KIT status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

KMT2A is altered in 3.61% of T-cell and NK-cell neoplasm patients [2].

KMT2A is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

MECOM is altered in 4.43% of T-cell and NK-cell neoplasm patients [2].

MECOM is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MECOM status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

NPM1 is altered in 1.01% of T-cell and NK-cell neoplasm patients [2].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

PBX1 is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PBX1 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RPN1 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].

TCF3 is altered in 0.98% of T-cell and NK-cell neoplasm patients [2].

TCF3 is an inclusion eligibility criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [3].